[1] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. J Hepatol. 2016;64:73-84; doi.org/10.1002/hep.2016.28431.
[2] De Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1: S104-112; doi.org/10.1016/hep.2008. 009.
[3] Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and epatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World J Gastroenterol. 2015;21:12989-12995; doi.org/ 10.3748/wjg.2015.12989.
[4] Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease. Hepatol Res. 2017;48(3):E42-E51; doi.org/ 10.1111/hepr.12925.
[5] Brouwers B, Schrauwen-Hinderling VB, Jelenik T, Gemmink A, Havekes B, Bruls Y, DahlmansD, Roden M, Hesselink MKC, Schrauwen P . Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2diabetes. Clin Sci (Lond). 2017;131(15):1905-1917; doi.org/10.1042/CS20170261.
[6] Nagpal SJ, Lopez R, Feldstein AE, Alkhouri N Serum cytokeratin-18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD. Liver Int. 2015;35:2621; doi.org/ 10.1111/liv.2015.12862.
[7] Yu-Hung Chang, Hsien-Chang Lin, Der-Wei Hwu, Dao-Ming Chang, Kun-Chen Lin, Yau-Jiunn Lee. Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Ann Clin Biochem. 2019;56(1):141-147; doi.org/10.1177/0004563218796259.
[8] Alberti KG, Zimmet PZ. Definition diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
[9] Farrell GC, Chitturi S, Lau GK, Sollano JD. Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepato. 2007;22:775-777.
[10] Jie Ming, Shaoyong Xu, Bin Gao, Guocai Liu, Yufei Ji, Fan Yang, Yunan Jia, Yujie Fang and
Qiuhe Ji. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but
not prediabetes, in Xi'an, China: a five-year cohort study. Liver Int. 2015;35:2401-2407;
doi.org/ 10.1111/liv.2015.12851.
[11] Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol. 2007;22:1086-1091.
[12] Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med. 2008;25:476-481; doi.org/ 10.1111/j.1464-5491.2008.02410.
[13] Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol. 2010;25:352-356; doi.org/ 10.1111/j.1440-1746.2009.05998.
[14] Zelber-Sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-Kaluski D, Halpern Z, Santo E, Oren R. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 2013;33:1406-1412; doi.org/10.1111/liv.12200.
[15] Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care.2012;35:717-722; doi.org/10.2337/dc11-1853.
[16] Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007;30:2940-2944; doi.org/ 10.2169/internalmedicine.2007.7115.
[17] Fukuda T, Hamaguchi M, Kojima T, Mitsuhashi K, Hashimoto Y, Ohbora A, Kato T, Nakamura N, Fukui M. Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men. Eur J Gastroenterol Hepatol. 2016;12:1443-1449; doi.org/ 10.1097/MEG.0000000000000736.
[18] Heianza Y, Arase Y, Tsuji H, Fujihara K, Saito K, Hsieh SD, Tanaka S, Kodama S, Hara S, Sone H. Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). J Clin Endocrinol Metab. 2014;99:2952-2960; doi.org/10.1210/jc.2013.4427.
[19] Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, Park SW, Kim SW. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care. 2011;34:727-729; doi.org/10.2337/dc10-1991.
[20] Kotronen A, Laaksonen MA, Heliövaara M, Reunanen A, Tuomilehto J, Yki-Järvinen H, Peltonen M, Knekt P. Fatty liver score and 15-year incidence of type 2 diabetes. Hepatol Int.2013;7:610-621; doi.org/ 10.1007/s12072-013-9430-7.
[21] Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57:1378-1383; doi.org/10.1002/hep.2013.26183.
[22] Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936–944; doi.org/ 10.1111/jgh.2016.13264.
[23] Nobili V, Mantovani A, Cianfarani S, Alisi A, Mosca A, Sartorelli MR, Maffeis C, Loomba R, Byrne CD, Targher G. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. J.Hepatol.2019; doi.org/ 10.1016/j.jhep.2019.06.023
[24] Ming J, Xu S, Gao B, Ji Q. Response to Serum cytokeratin-18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD. Liver Int. 2015;35:2622. https:// doi.org/10.1111/liv.2015.12867.
[25] Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-750.
[26] Williamson RM, Perry E, Glancy S, Marshall I, Gray C, Nee LD, Hayes PC, Forbes S, Frier BM, Johnston GI, Lee AJ, Reynolds RM, Price JF, Strachan MW. Edinburgh Type 2 Diabetes Study investigators. The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: intra- and interobserver variability and comparison with magnetic resonance spectroscopy. Clin Radiol.2011;66:434-439; doi.org/10.1016/j.crad.2010.09.021.
[27] Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 2009;41:265-278; doi.org/10.1080/07853890802552437.
[28] Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2009;28:2-12; doi.org/10.1111/j.1365-2036.2008.03710.
[29] Galluzzi L1, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell Death Differ.2007;14:1237-1243.
[30] Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology.2003;125:437-443.
[31] Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M, Nagaya T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, Tanaka E, Sano K. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin Gastroenterol. 2010;44:440-447; doi.org/10.1097/MCG.0b013e3181bdefe2.
[32] Wieckowska A1, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27-33.
[33] Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol. 2010;13:837-844.
[34] Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2010;24:564-568.
[35] Mandelia C, Collyer E, Mansoor S, Lopez R, Lappe S, Nobili V, Alkhouri N. Plasma Cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2016;63:181–187; doi.org/10.1097/MPG.0000000000001136.
[36] Arab JP, Hernández-Rocha C, Morales C, Vargas JI, Solís N1, Pizarro M, Robles C, Sandoval D, Ponthus S, Benítez C, Barrera F, Soza A, Riquelme A, Arrese M. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population. Gastroenterol Hepatol. 2017;40:388-394; doi.org/10.1016/j.gastrohep.2017.02.009.
[37] De Silva NMG, Borges MC, Hingorani AD, Engmann J, Shah T, Zhang X, Luan J, Langenberg
C, Wong A, Kuh D, Chambers JC, Zhang W, Jarvelin MR, Sebert S, Auvinen J; UCLEB consortium, Gaunt TR, Lawlor DA. Liver Function and Risk of Type 2 Diabetes: Bidirectional Mendelian Randomization Study. Diabetes. 2019;8:1681-1691; doi.org/ 10.2337/db18-1048.
[38] Mu W, Cheng XF, Liu Y, Lv QZ, Liu GL, Zhang JG, Li XY. Potential Nexus of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin resistance between Hepatic and Peripheral Tissues. Front Pharmacol 2019; doi.org/10.3389/fphar.2018.01566.